je.st
news
Tag: astrazeneca
Lilly And AstraZeneca Expand Immuno-Oncology Research Collaboration With New Combinations
2015-10-26 04:26:54| drugdiscoveryonline News Articles
Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE:AZN) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.
Tags: research
expand
collaboration
combinations
Premarket Biotech Digest: Gilead's Upcoming Earnings, Setback For AstraZeneca, Zafgen Tumbles 50%
2015-10-19 16:04:07| Biotech - Topix.net
The consensus forecast for Q3 revenue is at $7.81 billion, which is below the $8.24 billion reported in the previous quarter. The slight decline in revenue is due to a slowdown in the U.S. Hep C sales.
Tags: upcoming
earnings
digest
biotech
AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing...
2015-10-15 23:17:26| Biotech - Topix.net
Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial. The companies will now also evaluate the immunotherapy combination of Peregrine's phosphatidylserine -targeted immune-activator, bavituximab, and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab , in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer .
Tags: expand
ongoing
pharmaceuticals
peregrine
The Good News Continues For AstraZeneca
2015-09-11 09:30:06| Biotech - Topix.net
The good news continues to pour in for shares of AstraZeneca . I would like to highlight four key factors that make AZN a compelling low-risk play in today's turbulent marketplace.
Tags: news
good
continues
good news
Valeant, AstraZeneca strike psoriasis deal
2015-09-01 13:41:52| Biotech - Topix.net
Canada's Valeant Pharmaceuticals International Inc. has struck a deal with AstraZeneca PLC for the rights to sell psoriasis treatment brodalumab after Amgen Inc. dropped its own collaboration with the U.K.-based drug maker over concerns about the drug's side effects. Valeant said on Tuesday that it will pay AstraZeneca $100 million upfront, with another $170 million in prelaunch milestones and up to $175 million following launch.
Tags: deal
strike
psoriasis
astrazeneca
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »